High Squeeze Risk Profile
Recursion Pharmaceuticals (RXRX) has emerged as a primary target for short-selling scrutiny, currently holding the top spot on the Tapeboard live short interest rankings. With a squeeze score of 90.2, the stock is exhibiting classic signs of a crowded trade. Data indicates that 30.8% of the company's float is currently sold short, creating a volatile environment where any positive price momentum could trigger a rapid covering event.
Market Dynamics
While the borrow fee remains relatively modest at 0.5%, the high short interest percentage combined with a days-to-cover ratio of 4.9 suggests that short sellers are deeply entrenched. Investors should note that this data reflects the most recent settlement period. As a 'Threshold' security, RXRX is subject to specific regulatory monitoring regarding fails-to-deliver, which often accompanies high-short-interest scenarios. Market participants should monitor for any sudden spikes in borrow costs, which would indicate a tightening of lendable supply and an increase in the cost of maintaining these bearish positions.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.